Hester Biosciences closes trading window from October 1 for Q2FY27
- Trading window closed from October 1, 2026
- Closure applies to Q2FY27 and H1FY27 results
- Window reopens 48 hours after results are public
- Compliance with SEBI insider trading regulations

*this image is generated using AI for illustrative purposes only.
Hester Biosciences has closed its trading window for dealing in equity shares starting October 1, 2026. This measure is implemented ahead of the announcement of financial results for the quarter and six months ended September 30, 2026.
Regulatory compliance and timeline
The company stated that the closure is pursuant to the SEBI (Prohibition of Insider Trading) Regulations and its internal code of conduct. This code regulates and monitors trading by directors, promoters, designated employees, specified connected persons, and material subsidiaries, including their immediate relatives.
The trading window will remain closed until 48 hours after the financial results become generally available as public information. This standard protocol ensures that insiders do not trade while possessing unpublished price-sensitive information.
Key dates and details
| Detail | Information |
|---|---|
| Company | Hester Biosciences |
| Closure Start Date | October 1, 2026 |
| Reporting Period | Q2FY27 and H1FY27 |
| Period End Date | September 30, 2026 |
| Reopening Condition | 48 hours post-publication |
The communication was signed by Vinod Mali, Company Secretary and Compliance Officer, on September 25, 2026. The notice was filed with both BSE Limited and the National Stock Exchange of India Limited.
Historical Stock Returns for Hester Biosciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.10% | -2.08% | -7.00% | +60.48% | +12.28% | -11.95% |
How might Hester Biosciences' Q2FY27 revenue performance compare to the previous quarter given recent trends in the veterinary vaccine market?
What impact could the upcoming financial results have on Hester Biosciences' stock volatility once the trading window reopens?
Are there any pending regulatory approvals or new product launches expected to influence the company's earnings outlook for FY27?


































